Is Cerianna approved by the FDA?
Yes, Cerianna (fluoroestradiol F 18) is FDA approved. The U.S. Food and Drug Administration (FDA) approved Cerianna on May 20, 2020.
What is Cerianna?
Cerianna, with the generic name fluoroestradiol F 18, is a diagnostic radiopharmaceutical. It is used in combination with a PET scan to help detect estrogen receptor (ER)-positive lesions in patients with recurrent or metastatic breast cancer. This is crucial for identifying ER-positive lesions, which can influence treatment decisions.
How Does Cerianna Work?
As a radiopharmaceutical, fluoroestradiol F 18 works by emitting positrons that can be detected by a PET scanner. This allows doctors to create detailed images of estrogen receptor-positive lesions, aiding in the diagnosis and treatment planning for patients with recurrent or metastatic breast cancer.
Dosage and Administration
Cerianna is administered via an intravenous injection by a healthcare professional trained in nuclear medicine, just before undergoing a PET scan. Patients are advised to stay hydrated before the scan and continue to drink fluids and urinate frequently after the injection to minimize radiation exposure.
Side Effects
Common side effects of Cerianna may include:
- Change in or loss of taste
- Pain, redness, or irritation at the injection site
While these side effects are rare, it is important to monitor for any adverse reactions and consult with a healthcare provider if any symptoms are bothersome or persistent.
Precautions
- Pregnancy: It is crucial to inform your doctor if you are pregnant before receiving this medication.
- Interactions: Some medications, such as fulvestrant and tamoxifen, can interact with Cerianna by acting on estrogen receptors, potentially affecting its efficacy. Always inform your doctor about any other medications you are taking.
Conclusion
Cerianna (fluoroestradiol F 18) is an FDA-approved diagnostic tool that aids in the detection of estrogen receptor-positive breast cancer lesions through PET scans. Approved on May 20, 2020, it plays a significant role in the management of recurrent or metastatic breast cancer, offering valuable information that helps tailor treatment plans. As with any diagnostic tool, it should be administered under the supervision of a trained healthcare professional, and patients should be aware of potential side effects and interactions with other medications.
How to obtain the latest development progress of all drugs?
In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!
